Selected clinical trials of neoadyuvant therapy for resectable pancreatic cancer
| Author | Year | N | Neoadjuvant regimen | Resected (%) | Resected 0 (%) | Survival | Clinical trial |
|---|---|---|---|---|---|---|---|
| Chemoradiotherapy | |||||||
| 2002 | 35 | CCRT Paclitaxel+RT (30 Gy)+IORT |
57 | 68 | 28% (3-yr) 19 (mo) R |
Phase II | |
| Talamonti et al.48 | 2006 | 20 | CCRT Gem+RT (36 Gy) |
85 | 94 | 26 (mo) R | Phase II |
| 2008 | 86 | CCRT Gem, 400 mg/m2 weekly×7+RT, 30 Gy |
74 | 89 | 27% (5-yr) 34 (mo) R |
Phase II | |
| Chemottherapy followed by chemoradiation | |||||||
| 2008 | 90 | Gem, 750 mg/m2+cisplatin 30 mg/m2 → CCRT Gem, 400 mg/m2+RT, 30 Gy |
66 | 96 | 31 (mo) R | Phase II | |
| Christians et al.45 | 2016 | 69 | Chemotherapy (various) and chemoradiation | 87 | 97 | 31.5 (mo) 44, 9 (CT) |
Retrospective |
| Chemotherapy alone | |||||||
| Palmer et al.49 | 2007 | 50 | Gemcitabine vs Gemcitabine+Cisplatino | Gem: 38 Gem+Cis: 70 |
Gem: 75 Gem+Cis: 75 |
Gem: 42 (1-yr) | Phase II |
| Heinrich et al.50 | 2008 | 28 | Gem, 1 g/m2, Cis, 50 mg/m2 | 93 | 80 | 26.5 (mo) | Phase II |
| O’Reilly et al.51 | 2014 | 38 | Gem, 1 g/m2, Oxa, 80 71 mg/m2 | 71 | 74 | 63% (1, 5-yr) 27.2 (mo) |
Phase II |
*MDACC Clinical trials Phase II
R, resected; Gem, gemcitabine; Cis, cisplatino; Oxa, oxaliplatino; Gy, gray; IORT, intraoperative radiotherapy; mo, months; yr, years, CCRT, concurrent chemoradiation; RT, radiotherapy; CT, complete treatment